| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/11/2010 | WO2010007494A3 New composition for the treatment of ecchymotic pigmentations |
| 03/11/2010 | WO2010007232A9 Novel rapid-effect pharmaceutical forms and uses of resulting pharmaceutical compositions |
| 03/11/2010 | WO2010005732A3 Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| 03/11/2010 | WO2010005723A3 Drug loaded polymeric nanoparticles and methods of making and using same |
| 03/11/2010 | WO2010005721A3 Drug loaded polymeric nanoparticles and methods of making and using same |
| 03/11/2010 | WO2010001267A3 Delivery product for topical compositions |
| 03/11/2010 | WO2009157711A3 Gastro-retentive porous tablet and method for preparing same |
| 03/11/2010 | WO2009154810A3 Delivery systems for multiple active agents |
| 03/11/2010 | WO2009151295A3 Pharmaceutical formulation comprising azelnidipine and hmg-coa reductase inhibitor or angiotensin ii receptor blocker |
| 03/11/2010 | WO2009149317A3 Transmucosal delivery of therapeutic agents and methods of use thereof |
| 03/11/2010 | WO2009145594A3 Drug delivery carrier |
| 03/11/2010 | WO2009142772A3 Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| 03/11/2010 | WO2009142421A3 Pharmaceutical preparation (pharmaceutical formulation) |
| 03/11/2010 | WO2009141738A3 Modified drugs for use in liposomal nanoparticles |
| 03/11/2010 | WO2009139589A3 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant |
| 03/11/2010 | WO2009134086A9 Pharmaceutical formulation for treatment of cardiovascular disease |
| 03/11/2010 | WO2009134079A9 Pharmaceutical formulation |
| 03/11/2010 | WO2009134056A9 Pharmaceutical formulation |
| 03/11/2010 | WO2009131939A3 Lipid-containing compositions and methods of use thereof |
| 03/11/2010 | WO2009130712A3 Controlled release pharmaceutical compositions of trospium |
| 03/11/2010 | WO2009129510A4 Sulindac formulations in a biodegradable material |
| 03/11/2010 | WO2009129433A4 Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| 03/11/2010 | WO2009129120A3 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| 03/11/2010 | WO2009118756A3 Delayed release compositions of duloxetine |
| 03/11/2010 | WO2009118658A3 Endoplasmic reticulum targeting liposomes |
| 03/11/2010 | WO2009116047A3 Solid dosage form for treating headaches |
| 03/11/2010 | WO2009100176A3 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| 03/11/2010 | WO2009087633A3 Methods and compositions for oral administration of protein and peptide therapeutic agents |
| 03/11/2010 | WO2009053711A3 Method of encapsulation |
| 03/11/2010 | WO2009047785A9 A non-aqueous topical solution of diclofenac and process for preparing the same |
| 03/11/2010 | WO2009037482A3 Microcapsules and methods |
| 03/11/2010 | US20100063459 Gelatin-transglutaminase hemostatic dressings and sealants |
| 03/11/2010 | US20100063140 Water-soluble compositions of bioactive lipophilic compounds |
| 03/11/2010 | US20100063134 comprising the steps of surgically implanting a catheter ; without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity; Alzheimer's, Parkinson's, Huntington's diseases, Spinocerebellar Ataxia Type 1, Type 2, Type 3, and/or dentatorubral-pallidoluysian atrophy |
| 03/11/2010 | US20100063019 Low Dose Estrogen Interrupted Hormone Replacement Therapy |
| 03/11/2010 | US20100063010 Method for administering a spill resistant pharmaceutical system |
| 03/11/2010 | US20100062976 Synthesis of Cyclosporin Analogs |
| 03/11/2010 | US20100062073 Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| 03/11/2010 | US20100062072 Method for the delivery of a biologically active agent |
| 03/11/2010 | US20100062071 Particle Formulations and Uses Thereof |
| 03/11/2010 | US20100062070 Pulverzed crystals of olmesartan medoxomil |
| 03/11/2010 | US20100062069 Process for preparing particles containing an antiviral |
| 03/11/2010 | US20100062068 Cistus extracts |
| 03/11/2010 | US20100062067 Compositions comprising macromolecular assemblies of lipid and surfactant |
| 03/11/2010 | US20100062066 Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
| 03/11/2010 | US20100062065 Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system |
| 03/11/2010 | US20100062064 Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof |
| 03/11/2010 | US20100062063 Light-stable solid pharmaceutical composition of ramosetron |
| 03/11/2010 | US20100062062 Stabilized Coating for Pharmaceutical Formulations |
| 03/11/2010 | US20100062061 Method For Making Cetirizine Tablets |
| 03/11/2010 | US20100062060 Pharmaceutical composition comprising tramadol and ketoprofen in association |
| 03/11/2010 | US20100062059 S-Nitrosothiols Containing Composition for the Treatment of Fatty Liver Diseases, Obesity and Other Diseases Associated with the Metabolic Syndrome and the Use of Such Compositions |
| 03/11/2010 | US20100062058 Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using Same |
| 03/11/2010 | US20100062057 Formulation |
| 03/11/2010 | US20100062056 Encapsulated picoplatin |
| 03/11/2010 | US20100062055 Lipid-based nitric oxide donors |
| 03/11/2010 | US20100062054 Lipobeads and their production |
| 03/11/2010 | US20100062053 Cholestanol derivative for combined use |
| 03/11/2010 | US20100062052 Peptide-based compounds as new inhibitors of metalloectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses |
| 03/11/2010 | US20100062051 Composition for treatment of cervix cancer |
| 03/11/2010 | US20100062050 Means and methods of enhancing delivery to biological systems |
| 03/11/2010 | US20100062049 Aqueous formulation for selective targeting and delivering gene to cancer cells |
| 03/11/2010 | US20100062048 Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds |
| 03/11/2010 | US20100062047 Composition for Administration to Mammals or Human |
| 03/11/2010 | US20100062046 Polymorphs of nicotinic intermediates |
| 03/11/2010 | US20100062045 Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed |
| 03/11/2010 | US20100062044 Method and a product to reduce and treat problems associated with tinea pedis |
| 03/11/2010 | US20100062043 Methods, Systems and Devices for Administration of Chlorine Dioxide |
| 03/11/2010 | US20100062042 Methods, Systems and Devices for Administration of Chlorine Dioxide |
| 03/11/2010 | US20100062041 Skin sunstitutes, preparation methods and uses thereof |
| 03/11/2010 | US20100062040 Water soluble drugs and supplements |
| 03/11/2010 | US20100062037 Subcutaneous implants releasing an active principle over an extended period of time |
| 03/11/2010 | US20100062034 Membrane shell of an implantable dosage system |
| 03/11/2010 | US20100062029 Product for the Targeted Release of Active Substances |
| 03/11/2010 | US20100061941 Tooth whitening compositions and delivery systems therefor |
| 03/11/2010 | US20100061940 Chewing Gum Compositions Providing Rapid Release of Nicotine |
| 03/11/2010 | US20100061939 Chewing Gum |
| 03/11/2010 | CA2736119A1 Chewable sustained release formulations |
| 03/11/2010 | CA2736024A1 Pharmaceutical solid preparation |
| 03/11/2010 | CA2735793A1 Antiviral agent |
| 03/11/2010 | CA2735709A1 Agent for treating myelofibrosis |
| 03/11/2010 | CA2735431A1 Co-crystals and pharmaceutical formulations comprising the same |
| 03/11/2010 | CA2735037A1 Tabletting of erythritol |
| 03/11/2010 | CA2734919A1 Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| 03/11/2010 | CA2734691A1 Method for making cetirizine tablets |
| 03/11/2010 | CA2734588A1 Silver ion delivery platform |
| 03/11/2010 | CA2734525A1 Sustained release formulations using non-aqueous carriers |
| 03/11/2010 | CA2734517A1 Pharmaceutical composition having relatively low ionic strength |
| 03/11/2010 | CA2733823A1 Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue |
| 03/10/2010 | EP2161050A1 Transdermal absorption type patch |
| 03/10/2010 | EP2161036A1 Cellulose fine core particle, and method for production thereof |
| 03/10/2010 | EP2161022A1 Production of phosphate connectors and phosphate connectors produced according to the method |
| 03/10/2010 | EP2161021A1 Medicinal film preparation with rapidly dissolving property and flexibility |
| 03/10/2010 | EP2161020A1 Chelating amphiphilic polymers |
| 03/10/2010 | EP2161019A1 Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
| 03/10/2010 | EP2160185A1 Methods of making and using nano scale particles |
| 03/10/2010 | EP2160184A2 Hypercompressed particles for controlled release of ophthalmic medications |
| 03/10/2010 | EP2160183A1 Extended release formulations comprising quetipine and methods for their manufacture |
| 03/10/2010 | EP2160182A1 Formulations and methods for treating dry eye |
| 03/10/2010 | EP1660104B1 Pharmaceutical formulation comprising lanthanum compounds |